(CHRS) Coherus Oncology, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CHRS) Coherus Oncology, Inc. Complete Analysis Pack
Coherus Oncology’s Business Model, in One Clear View
Unlock the full strategic blueprint behind Coherus Oncology, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, builds partnerships, and positions itself in oncology. Ideal for investors, strategists, and analysts looking for actionable insights—get the full version to explore every key building block.
Partnerships
Junshi Biosciences toripalimab alliance
Junshi Biosciences is the core partner behind LOQTORZI/toripalimab: Coherus co-develops and commercializes the asset under a 2021 deal, and toripalimab became the first FDA-approved anti-PD-1 for nasopharyngeal carcinoma in 2023. This alliance gives Coherus a next-generation immuno-oncology product and anchors its shift beyond biosimilars.
Surface collaboration and licensing
Surface is named in both collaboration and licensing agreements, giving Coherus Oncology access to external immunotherapy discovery and development without owning every asset outright. This model helps expand pipeline reach and lower upfront R&D burden, which matters as Coherus Oncology scales with a leaner capital base in 2025 filings.
Adimab LLC antibody discovery support
Adimab LLC gives Coherus Oncology, Inc. antibody discovery support for its oncology pipeline, helping generate and optimize monoclonal antibody candidates for solid tumors and immune targets. This kind of platform support can shorten early discovery work and improve the quality of lead assets before Coherus Oncology, Inc. moves into later-stage testing.
Bioeq AG biosimilar licensing
Bioeq AG gives Coherus Oncology, Inc. biosimilar rights tied to CIMERLI, the first FDA-approved ranibizumab biosimilar, with 2 strengths: 0.3 mg and 0.5 mg. That licensing link supports commercialization and keeps access open to external biologics programs, helping Coherus build its ophthalmology franchise without full in-house discovery spend.
- 1 FDA-approved biosimilar program
- 2 dose strengths in market
- External rights, lower R&D burden
Genentech, Novartis, GSK and Vaccinex agreements
Coherus Oncology, Inc. keeps licensing and out-licensing ties with Genentech, Novartis Institutes for Biomedical Research, GlaxoSmithKline Intellectual Property No. 4 Limited, and Vaccinex, which widens access to external technology and creates more ways to monetize assets. These agreements also support a more diversified intellectual property base, reducing dependence on any single program.
- Four key partners support licensing reach
- Out-licensing adds monetization paths
- Diversified IP helps reduce concentration risk
Key Partnerships Power Coherus Oncology’s Pipeline
Key partnerships center on Junshi Biosciences for LOQTORZI, Adimab for antibody discovery, Surface for immunotherapy licensing, and Bioeq for CIMERLI rights. These deals give Coherus Oncology, Inc. external R&D scale and 1 FDA-approved anti-PD-1 asset plus 1 FDA-approved biosimilar program, cutting upfront spend while broadening the pipeline.
| Partner | Role |
|---|---|
| Junshi | LOQTORZI co-development |
| Adimab | Antibody discovery |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas of Coherus Oncology, Inc., mapping how it develops, commercializes, and partners on oncology therapies.
Customizable Excel Spreadsheet
Fast view of Coherus Oncology’s business model, helping teams spot pain points and align strategy quickly.
Reference Sources
Provides a traceable source trail for Coherus Oncology, Inc., strengthening credibility and speeding investor due diligence.
Activities
Biopharmaceutical R&D
Coherus Oncology, Inc. centers biopharmaceutical R&D on cancer immunotherapies and biologics, advancing marketed oncology products alongside clinical-stage assets such as LOQTORZI, casdozokitug, and CHS-114. Discovery and translational work stay core, because moving science from lab to clinic is what turns its pipeline into revenue.
Clinical development of pipeline assets
Coherus Oncology advances 5 pipeline assets—LOQTORZI, Casdozokitug, CHS-114, CHS-1000, and GSK4381562—through trial design, regulatory talks, and data generation. Clinical execution drives each readout and is the main gate to future approvals, with LOQTORZI already showing the model’s commercial path after its FDA approval in 2023.
Biosimilar commercialization
Coherus Oncology commercializes UDENYCA, YUSIMRY, and CIMERLI to keep biosimilars on the market and drive revenue; in 2024, net product revenue was $320.7 million. This activity relies on market access, distribution, and promotion to defend share in a price-sensitive oncology biosimilars market.
Regulatory and quality operations
Regulatory and quality operations keep Coherus Oncology, Inc. aligned with FDA rules, cGMP, and pharmacovigilance, which is critical for biologics where one lapse can delay approval or trigger a supply hold. They also manage lifecycle changes, batch release, and complaint tracking to protect market access and patient safety.
- FDA compliance and quality control
- Pharmacovigilance and safety reporting
- Lifecycle changes and supply continuity
Partner management and licensing execution
Coherus Oncology, Inc. relies on partner management and licensing execution to negotiate, maintain, and monetize co-development, licensing, and out-licensing deals. This is a core operating function because partnered assets can drive cash flow, lower R&D burden, and extend reach without full internal commercialization.
- Negotiate and renew collaboration terms
- Run co-development and licensing deals
- Monetize out-licensed assets and royalties
The function matters most where one partner funds development and another handles execution, so deal quality and compliance directly affect revenue capture and portfolio value.
Coherus Oncology: $320.7M Revenue Powering Biosimilar Growth
Coherus Oncology, Inc. runs its business on three core activities: oncology R&D, biosimilar commercialization, and regulatory/quality control. In 2024, net product revenue was $320.7 million, showing how manufacturing, market access, and compliance convert approved assets into cash.
| Key activity | 2024 data |
|---|---|
| Net product revenue | $320.7 million |
| Commercial products | UDENYCA, YUSIMRY, CIMERLI |
What You See Is What You Get
Business Model Canvas
This preview of the Coherus Oncology, Inc. Business Model Canvas is the exact document you’ll receive after purchase. It is not a sample or mockup—what you see here is a direct snapshot of the final file.
Once you complete your order, you’ll get the same professionally formatted, ready-to-use document in full. No surprises, no hidden changes—just the complete version exactly as previewed.
Resources
Commercial brands UDENYCA, YUSIMRY, CIMERLI
UDENYCA, YUSIMRY, and CIMERLI are Coherus Oncology, Inc.'s key revenue engines, with the portfolio helping fund operations while the oncology pipeline matures. In 2025, these marketed biosimilars gave the Company near-term commercial scale, and strong brand recall plus payer access remained critical to sustaining share and cash flow.
Oncology pipeline LOQTORZI and next-gen antibodies
Coherus Oncology, Inc. core innovation inventory includes 5 pipeline assets: LOQTORZI, Casdozokitug, CHS-114, CHS-1000, and GSK4381562. LOQTORZI is already an approved PD-1 therapy, while the next-gen antibodies broaden the shot at future growth, higher label expansion, and new combinations.
Intellectual property and licensed rights
Coherus Oncology, Inc. depends on patents, in-licensed rights, and out-licensing to protect assets like LOQTORZI, the first and only FDA-approved anti-PD-1 for nasopharyngeal carcinoma in the U.S. In biologics, where U.S. exclusivity can run up to 12 years, that IP shield is what supports pricing power, partnering income, and longer-lived value.
Scientific and regulatory expertise
Coherus Oncology, Inc. needs scientific and regulatory expertise to build antibodies, manage biosimilars, and run FDA filings. This intangible resource matters because one approved drug, LOQTORZI, and a biosimilar base still depend on strong CMC, clinical, and label work to reach market.
- Supports development and filings
- Drives commercialization speed
- Protects a key intangible asset
Partner network and commercialization infrastructure
Coherus Oncology, Inc. relies on strategic alliances and commercial operations to bring in external science, expand market access, and keep revenue optionality alive. Its Redwood City, California base anchors management and execution, which matters as the company shifts from a single-asset model to a broader oncology platform.
- Alliances add science and reach
- Commercial ops support revenue optionality
- Redwood City supports execution
Coherus Oncology’s Assets Power Near-Term Cash and Long-Term Growth
Coherus Oncology, Inc. key resources are UDENYCA, YUSIMRY, CIMERLI, plus its 5-asset oncology pipeline: LOQTORZI, Casdozokitug, CHS-114, CHS-1000, and GSK4381562. In 2025, these assets supported near-term cash flow while LOQTORZI and the antibody pipeline drove longer-term growth.
Patent rights, in-licensed IP, FDA know-how, and commercial access are the core assets that protect pricing and speed launches.
| Key resource | 2025 data |
|---|---|
| Commercial products | 3 biosimilars |
| Oncology pipeline | 5 assets |
| Approved PD-1 asset | LOQTORZI |
Value Propositions
Affordable access via biosimilars
Coherus Oncology, Inc. uses UDENYCA, YUSIMRY, and CIMERLI to give payers and providers lower-cost biosimilar options versus reference brands, expanding access in oncology, immunology, and ophthalmology. UDENYCA has been a top pegfilgrastim biosimilar in the U.S., and YUSIMRY and CIMERLI add competition in markets where brand biologics often cost tens of thousands of dollars per patient each year.
Oncology innovation with LOQTORZI
LOQTORZI adds a next-generation PD-1 inhibitor to Coherus Oncology, Inc.’s portfolio and shifts the mix beyond biosimilars toward branded oncology. It is the first and only FDA-approved treatment for recurrent or metastatic nasopharyngeal carcinoma in the U.S., giving the company a differentiated immunotherapy asset with clear clinical and commercial value.
Diversified biologics portfolio
Coherus Oncology, Inc. pairs marketed biosimilars with investigational immunotherapies, so it can use current cash flow from products like YUSIMRY and UDENYCA while funding future upside from its oncology pipeline. That mix lowers reliance on one asset class and, by the company’s latest filings, supports a broader base than a single-product model.
Targeted immune-oncology mechanisms
Coherus Oncology, Inc.’s value proposition is a five-axis immune-oncology pipeline that targets PD-1, IL-27, CCR8-like Treg biology, ILT4, and CD112R to push back on tumor microenvironment immune suppression. The goal is differentiated efficacy across hard-to-treat cancers, building on a portfolio that pairs one approved checkpoint asset with multiple next-gen mechanisms.
- Five immune-oncology targets
- Focus on tumor immune suppression
- Designed for differentiated efficacy
- Checkpoint plus next-gen biology
Partner-enabled speed and scale
Coherus Oncology, Inc. uses partner-enabled speed and scale to add external development capacity and broader scientific reach, so it can move more programs without building every team in-house. Co-development and licensing can also shorten time to market and spread risk across multiple assets, which matters when oncology R&D success rates stay low.
Key takeaways: faster execution; wider expertise; lower single-program risk.
Coherus Oncology: Low-Cost Biosimilars Today, High-Value Cancer Assets Tomorrow
Coherus Oncology, Inc. sells 3 marketed biosimilars and 1 approved branded oncology drug, so it can offer lower-cost access now while building higher-value cancer assets. Its pipeline spans 5 immune-oncology targets, with LOQTORZI as the only U.S.-approved drug for recurrent or metastatic nasopharyngeal carcinoma.
| Metric | Value |
|---|---|
| Marketed biosimilars | 3 |
| Approved branded oncology assets | 1 |
| Immune-oncology targets | 5 |
Customer Relationships
Institutional account management
Coherus Oncology, Inc. sells to hospitals, clinics, and large care systems through account-based teams because biosimilars depend on contracts, formulary access, and steady reorders. In U.S. biosimilars, where price cuts often run 15% to 30% versus the reference drug, deep relationships matter most in high-volume accounts that can place large, repeat orders.
Medical affairs and clinical education
Medical affairs and clinical education help Coherus Oncology, Inc. explain biosimilar interchangeability, dosing, and oncology evidence to physicians, pharmacists, and care teams. In a U.S. market with 45 FDA-approved biosimilars as of 2026, clear scientific guidance supports trust, faster uptake, and better site-of-care decisions.
Payer and reimbursement support
Access to Coherus Oncology, Inc. products depends on payer coverage, prior authorization, and reimbursement timing, so the company has to work closely with payers and specialty distributors to secure utilization. Support services that help with benefits checks, claims, and appeals reduce delays for patients and providers, which matters in oncology where treatment starts can’t wait.
Partner-led commercialization relationships
Coherus Oncology, Inc. uses partner-led commercialization for advanced programs, so contract governance and milestone delivery matter as much as science. With one approved oncology product, LOQTORZI, and a pipeline still tied to collaborators, trust and clean execution directly shape future value.
- Shared milestones drive progress
- Contract terms protect economics
- Partner trust supports pipeline value
Post-market safety and service support
Post-market safety and service support is critical for Coherus Oncology, Inc. because biologics need ongoing pharmacovigilance, complaint handling, and fast field support after launch. In regulated healthcare markets, this keeps prescribers and payers confident that safety signals are tracked and acted on quickly.
- Track safety after launch.
- Handle complaints fast.
- Protect customer trust.
Coherus Oncology Relies on Access, Reimbursement, and Field Support
Coherus Oncology, Inc. keeps customer ties tight with hospitals, payers, and specialty distributors because access, prior auth, and reimbursement drive uptake. In 2025, its oncology base centered on one approved product, LOQTORZI, so medical education, field support, and post-market safety tracking stayed central to repeat use.
| Metric | 2025 |
|---|---|
| Approved oncology products | 1 |
| U.S. biosimilars approved | 45 |
| Typical biosimilar discount | 15% to 30% |
Channels
Direct specialty sales force
Coherus Oncology, Inc. uses a direct specialty sales force to call healthcare providers and account teams, which fits oncology’s high-touch model and helps with product education and contract execution. This matters because specialty biologics often carry annual treatment costs above $100,000 per patient, so direct field teams can speed access and support adoption.
Wholesalers and distributors
Coherus Oncology, Inc. uses established pharmaceutical wholesalers and distributors to move biologics through the U.S. supply chain, which helps reach patients nationwide and keep product flowing. With the top 3 U.S. drug wholesalers handling most prescription-drug distribution, this channel supports fast fulfillment, inventory control, and broad access.
Specialty pharmacy networks
Specialty pharmacy networks are key for Coherus Oncology, Inc. because they handle complex dispensing, prior auth, reimbursement, and patient support for self-administered specialty products. Specialty medicines still make up only a small share of prescriptions but drive most drug spend, so access through these networks can shape uptake and refill rates.
Hospital and clinic procurement
Hospital and clinic procurement is a key gate for Coherus Oncology, Inc. because buy-and-bill still drives most infused and office-administered oncology access, and U.S. cancer demand stays high: the American Cancer Society projected about 2.0 million new cases in 2025. In practice, hospitals, IDNs, and oncology clinics decide formulary access, contract terms, and stocking speed, so procurement ties directly to uptake.
- Buy-and-bill shapes access.
- Hospitals and IDNs steer adoption.
- Procurement terms affect uptake.
Partner commercialization channels
Partner commercialization channels let Coherus Oncology, Inc. use collaborators to market, distribute, or co-promote assets, which extends reach beyond its own sales force. In FY2025, this matters most for global or specialized products like LOQTORZI, where partner-led channels can cut fixed selling costs and speed access in targeted markets.
- Uses partner sales reach
- Supports global expansion
- Lowers owned-infrastructure load
Coherus’ Oncology Sales Engine: Four Channels, One Access Mission
Coherus Oncology, Inc. leans on four channels: direct specialty sales, wholesalers and distributors, specialty pharmacies, and hospital or clinic procurement. This fits oncology’s high-touch model, where about 2.0 million new U.S. cancer cases were projected for 2025 and buy-and-bill still shapes access.
| Channel | Role |
|---|---|
| Direct sales | Educate providers |
| Wholesalers | Nationwide supply |
| Specialty pharmacy | PA and refill support |
| Hospitals | Formulary access |
Customer Segments
Oncology physicians and cancer centers
Oncology physicians and cancer centers are the key buyers for Coherus Oncology, Inc.'s LOQTORZI and pipeline drugs. They judge 1st-line efficacy, safety, and payer coverage fast, so adoption depends on strong clinical data plus smooth reimbursement and access.
Hospitals and integrated delivery networks
Hospitals and integrated delivery networks buy and administer specialty biologics, so they matter for UDENYCA and Coherus Oncology, Inc. cancer treatments. In a U.S. market with more than 5,000 hospitals, contract wins and formulary placement can decide access, volume, and repeat use.
Rheumatology and dermatology practices
Rheumatology and dermatology practices are key commercial users because they prescribe biologics for chronic autoimmune disease, including rheumatoid arthritis and psoriasis. In the U.S., about 1.5 million adults live with rheumatoid arthritis and nearly 8 million with psoriasis, creating a large base for YUSIMRY.
Ophthalmology providers
Ophthalmology providers are CIMERLI's core buyers and prescribers because the drug is used in retinal disease treatment settings, mainly by ophthalmologists and affiliated retina clinics. Access and office workflow matter a lot: anti-VEGF care is repeat-visit driven, so clinics favor products that fit prior auth, stocking, and injection-room routines.
- Primary prescribers: ophthalmologists
- Setting: retina and eye clinics
- Key need: fast access
- Key need: simple office workflow
Payers, PBMs, and health systems
Payers, PBMs, and health systems do not buy Coherus Oncology, Inc. products as patients do, but they drive biosimilar uptake through formulary placement, reimbursement, and site-of-care rules. In the U.S., Medicare alone covered about 68 million people in 2025, so value-based access and total-cost savings matter more than brand loyalty.
- Shape access, not direct demand
- Control reimbursement and formulary status
- Need lower net cost per treated patient
- Health systems favor proven real-world savings
Coherus’ key buyers: oncologists, payers, and specialty clinics
Coherus Oncology, Inc. sells to oncology physicians, cancer centers, hospitals, and integrated delivery networks that decide use, stocking, and reimbursement for LOQTORZI, UDENYCA, and pipeline drugs. Payers and PBMs shape access, while specialty clinics in rheumatology, dermatology, and ophthalmology drive repeat biologic use.
| Segment | Role | Need |
|---|---|---|
| Oncology | Prescribe/administer | Clinical data, coverage |
| Payers | Gate access | Lower net cost |
| Specialty clinics | Repeat use | Simple workflow |
Cost Structure
Research and development spend
Research and development is Coherus Oncology, Inc.’s main cost driver, because the pipeline needs heavy spend on discovery, preclinical work, and ongoing clinical trials across multiple assets. In its latest annual filing, R&D was the largest operating expense category, reflecting the cash needed to advance oncology programs through each trial phase.
Commercial launch and selling costs
Coherus Oncology, Inc. must keep spending on field teams, payer access, and promotion to launch and defend biosimilars and oncology products. Commercial scale still needs sustained outlays, and the company’s 2025 filing showed selling, general and administrative costs remained a major cash use.
Manufacturing and supply chain costs
For Coherus Oncology, Inc., manufacturing and supply chain spending stays heavy because biologics need sterile production, quality control, and cold-chain distribution; in 2025, these steps kept COGS and logistics among the biggest cash costs. Reliable supply matters for market trust, since even a short stockout can hit sales and margins fast.
Regulatory, compliance, and pharmacovigilance
Regulatory, compliance, and pharmacovigilance are non-discretionary costs for Coherus Oncology, Inc.: drug approval, FDA filing support, safety monitoring, and adverse-event reporting must run every year, even before revenue scales. These systems also require staff, validated databases, and regulatory documents to stay inspection-ready.
- Mandatory for every product lifecycle
- Drives fixed overhead and cash burn
- Protects approval and market access
- Requires ongoing safety reporting
General and administrative overhead
Coherus Oncology, Inc. keeps general and administrative overhead centered in Redwood City: headquarters, finance, legal, and administration, plus licensing and contract management that support the operating platform. In 2025, these public-company functions remained a fixed cost layer that sat above product-level work and helped keep compliance, reporting, and deal execution in place.
HQ, finance, legal, admin in Redwood City
Licensing and contract work add fixed overhead
Public-company costs support the platform
Coherus Keeps 2025 Spending Focused on R&D and Pipeline Growth
In 2025, Coherus Oncology, Inc. kept cost structure centered on R&D, because pipeline progress and clinical trials were the biggest cash uses. SG&A, COGS, and regulatory compliance stayed heavy too, since launch support, sterile biologics supply, and safety reporting all need fixed spend.
| Cost item | 2025 role |
|---|---|
| R&D | Largest operating expense |
| SG&A | Major cash use |
| COGS and logistics | Heavy biologics cost |
| Regulatory and safety | Non-discretionary overhead |
Revenue Streams
Product sales of UDENYCA
UDENYCA, a 6 mg long-acting G-CSF biosimilar, drives direct U.S. product sales for Coherus Oncology, Inc. It remains a core near-term revenue stream while the company keeps monetizing its commercial footprint in the U.S. biosimilar market.
Product sales of YUSIMRY
YUSIMRY, Coherus Oncology, Inc.’s adalimumab biosimilar, earns revenue from sales into large inflammatory disease markets such as rheumatoid arthritis and psoriasis. As part of the U.S. Humira biosimilar class, it adds a non-oncology cash stream and helps diversify biosimilar income.
Product sales of CIMERLI
CIMERLI, a 0.5 mg/0.05 mL ranibizumab biosimilar, adds ophthalmology revenue for Coherus Oncology, Inc. through commercialization in retinal and macular disorders such as wet AMD, diabetic macular edema, and retinal vein occlusion. It broadens the marketed portfolio beyond oncology and deepens repeat prescription sales.
Collaboration and milestone payments
Collaboration and milestone payments are a key non-dilutive revenue stream for Coherus Oncology, Inc.: partner deals can bring upfront cash, development reimbursements, and milestone fees as programs advance. The Junshi co-development tie-up helps Coherus monetize progress while funding R&D, reducing pressure on the balance sheet and extending runway.
- Upfront cash from partnerships
- Milestones tied to progress
- Funds ongoing development
Licensing and royalty income
Out-licensing lets Coherus Oncology, Inc. earn non-product revenue through royalties and other license fees from partnered assets, so the company can monetize IP even when it is not selling the drug itself. This stream matters because it can turn pipeline rights into cash without adding manufacturing or launch costs.
- Royalties come from partnered assets.
- License fees create non-product income.
- IP monetization supports pipeline value.
Coherus Revenue: U.S. Product Sales Lead, Partners Fund R&D
Coherus Oncology, Inc. earns most revenue from U.S. net product sales, led by UDENYCA, YUSIMRY, and CIMERLI. Smaller but useful income comes from collaboration cash, milestones, royalties, and license fees, which help fund R&D without extra debt.
| Stream | Type | Value driver |
|---|---|---|
| UDENYCA | Product sales | U.S. biosimilar demand |
| YUSIMRY | Product sales | Inflammatory disease sales |
| CIMERLI | Product sales | Retina market prescriptions |
| Partners | Non-product income | Milestones and royalties |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.